Company intelligence / Profile preview

AGEPHA Pharma

Senec, Bratislavsky, Slovakia

Ownership: Private
Employees: ~28
Development stage: Commercial

Overview

AGEPHA Pharma has received FDA approval for LODOCO (colchicine, 0.5 mg tablets) which reduces cardiac event risk in adult patients with established Atherosclerotic Cardiovascular Disease (ASCVD) by an additional 31% on top of standard of care including high intensity statins[3][7].

Therapeutic areas: DermatologyOphthalmologyCardiovascularMen's Health
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

colchicine

Commercial

Indications: Atherosclerotic Cardiovascular Disease

Beyond the preview

Go deeper on AGEPHA Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGEPHA Pharma.

Explore the full profile